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Abstract
Pancreatic adenocarcinoma is characterized by a complex tumor environment with a wide
diversity of infiltrating stromal and immune cell types that impact the tumor response to con-
ventional treatments. However, even in this poorly responsive tumor the extent of T cell infil-
tration as determined by quantitative immunohistology is a candidate prognostic factor for
patient outcome. As such, even more comprehensive immunophenotyping of the tumor
environment, such as immune cell type deconvolution via inference models based on gene
expression profiling, holds significant promise. We hypothesized that RNA-Seq can provide
a comprehensive alternative to quantitative immunohistology for immunophenotyping pan-
creatic cancer. We performed RNA-Seq on a prospective cohort of pancreatic tumor speci-
mens and compared multiple approaches for gene expression-based immunophenotyping
analysis compared to quantitative immunohistology. Our analyses demonstrated that while
gene expression analyses provide additional information on the complexity of the tumor
immune environment, they are limited in sensitivity by the low overall immune infiltrate in
pancreatic cancer. As an alternative approach, we identified a set of genes that were
enriched in highly T cell infiltrated pancreatic tumors, and demonstrate that these can iden-
tify patients with improved outcome in a reference population. These data demonstrate that
the poor immune infiltrate in pancreatic cancer can present problems for analyses that use
gene expression-based tools; however, there remains enormous potential in using these
approaches to understand the relationships between diverse patterns of infiltrating cells and
their impact on patient treatment outcomes.
PLOS ONE
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Introduction
Pancreatic cancer is commonly characterized by extensive desmoplastic stroma and an envi-
ronment that is poorly supportive of adaptive immune responses, yet like many other cancers,
the degree of T cell infiltrate in pancreatic tumors is correlated with patient outcome [1–4]. T
cells in pancreatic tumors face an array of suppressive mechanisms that can limit their ability
to control tumors, and it would be beneficial to understand the relationship between T cell
infiltration and the presence of other immune populations that positively or negatively regu-
late immune responses. For this reason, there is significant effort in the field to understand
and manipulate the complex immune environment of tumors.
Quantitative immunohistochemistry (IHC) has long represented the gold standard by
which tumor infiltrating immune populations can be assessed, and recent advances in multi-
spectral IHC combined with automated image analysis have made possible an unprece-
dented ability to map out the immune environment of tumors. However, these approaches
are limited by the availability and quality of antibodies, and complex multispectral panels
require extensive validation to confirm the specificity and selectivity of binding. Recently,
multiple groups have shown that the quantity of a diverse array of infiltrating immune cell
types in a specimen can be inferred based on characteristic gene expression patterns unique
to or enriched in specific cell types [5, 6]. In theory, a single RNA sequencing (RNA-Seq)
analysis of preserved tissue can provide an assessment of immune cell infiltration as well as
other information such as the cytokine and chemokine balance that may be regulating cell
entry and retention in the tissue, together with candidate features of the cancer cells that
orchestrate this environment. The addition of simultaneous whole exome sequencing can
permit comprehensive profiling of cancer driver mutations, immune targetable mutations,
as well as a personalized understanding of the patient’s immune profile [7, 8]. However, it
remains unclear whether IHC and gene expression-based immune assessment approaches
are highly concordant. For example, the utility of RNA-Seq in tumor profiling can be limited
by a range of unique factors including degradation of transcripts in excised human tissues
and by common tumor preservatives (e.g. formalin) and the ability to detect low-abundant
transcripts. The latter is of particular concern in pancreatic cancer, which can have a rela-
tively low infiltration of critical cell types such as CD8 T cells.
Thus far we are not aware of any studies that have directly compared IHC quantification
of immune infiltration to RNA-Seq-based analyses in pancreatic cancer. In this study we aim
to directly compare conventional IHC and gene expression-based approaches to characterize
the immune environment of pancreatic cancer. We hypothesize that RNA-Seq analysis can
provide a comprehensive alternative to quantitative IHC for immunophenotyping pancreatic
cancer. We performed RNA-Seq on a prospective cohort of 39 pancreatic adenocarcinoma
patient tumors with matched quantitative IHC, and evaluated approaches to quantify infil-
trating immune cells using gene expression data. We found limited agreement between IHC
and RNA-Seq analysis of infiltrating cells, however concordance was greatest when multiple
cell types were aggregated to identify a mixed population, such as CD3+ T cells from a com-
bination of CD4+, CD8+, and other cell types that express CD3. This aggregation may over-
come the limitation of low T cell-derived RNA transcripts in poorly-immune infiltrated
tumors. As an alternative, we identified gene signatures that were enriched in highly T cell
infiltrated tumors that are associated with increased disease-free survival in other patient
cohorts. These data demonstrate that immune infiltration remains an important predictor
of outcome in pancreatic cancer patients, and that RNA analysis can provide an important
addition to IHC data to understand the complexities of the immune environment that influ-
ence patient outcome.
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Methods
Quantitative immunohistology for infiltrating immune cells in pancreatic
cancer
We conducted a prospective cohort study of resectable pancreatic masses to determine which
immunologic parameters have prognostic value. All procedures were approved under Provi-
dence Portland Medical Center Institutional Review Board, with approval number IRB 10–
037, and patients provided written informed consent. We restricted our analysis to adult
patients who underwent surgical resection for pancreatic masses. Patients were recruited from
June 2010 to November 2014 at Providence Portland Medical Center in Portland, OR, where
the research was conducted. Inclusion criteria included patients 18 years or older who had
a diagnosis of a pancreatic or ampullary mass who were scheduled for surgical resection.
Patients had to be able to give informed consent and could not have a diagnosis of a prior
malignancy unless they were disease free for 10 years. We included patients who were subse-
quently determined to have other histologies. Demographics and survival of these patients
are outlined in Table 1. Prior studies on this cohort had identified a positive correlation
between CD3+ T cell infiltrate and overall survival by Multivariate Cox modeling and univari-
ate analysis [1], so this sample set was applied for additional genomic analysis. Additional
power calculations were not performed. Tumor infiltrating immune cells were quantified by
immunohistochemistry and quantitative digital image analysis for CD3+, CD68+, and CD8+
cells as previously described [1]. Infiltrating cells were quantified from whole slide digital
Table 1. Demographics of patients on the study.
Characteristic Data
Pancreatic Adenocarcinoma, n 75
Age,median (range), y 66 (25–87)
Male, n (%) 43 (57%)
Female, n (%) 32 (43%)
Neoadjuvant treated PDA, n 6
Age,median (range), y 61 (58–61)
Male, n (%) 3 (50%)
Female, n (%) 3 (50%)
Premalignant, n 13
Age,median (range), y 58 (28–79)
Male, n (%) 5 (38%)
Female, n (%) 8 (62%)
Benign, n 10
Age,median (range), y 53 (40–71)
Male, n (%) 5 (50%)
Female, n (%) 5 (50%)
Neuroendocrine, n 3
Age,median (range), y 61 (55–69)
Male, n (%) 2 (66%)
Female, n (%) 1 (33%)
Duodenal Adeonocarcinoma, n 1
Age,median (range), y 61
Male, n (%) 1 (100%)
Female, n (%) 0 (0%)
https://doi.org/10.1371/journal.pone.0238380.t001
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images scanned at 20x resolution (Leica SCN400). Regions of interest were defined with
Pathologist guidance using Definiens Tissue Studio (Definiens Inc), and the automated algo-
rithm used the immunohistology staining combined with nuclear counterstain to count total
cells and positive cells to report a marker positive cell density per mm2 tissue for each patient.
Primary outcome was overall survival.
RNASeq analysis of pancreatic cancer
Of the patients above with pancreatic masses, we randomly selected 39 patients with patholog-
ically diagnosed pancreatic adenocarcinoma with no neoadjuvant treatment and with matched
quantitative IHC for RNASeq. All subsequent analyses of IHC and RNASeq were performed
on unpretreated patients. A representative Hematoxylin and Eosin (H&E) stained slide for
each formalin-fixed paraffin-embedded (FFPE) tissue block specimen was reviewed by a
board-certified pathologist for tumor content and tumor-rich regions were identified for
microdissection. Blocks were matched but not in series with IHC sections. 5 μm thick
unstained sections on glass slides were processed for DNA and RNA purification by the Provi-
dence Molecular Genomics Laboratory. The FFPE tissue sections were deparaffinized using
Envirene (Hardy Diagnostics) followed by RNA extraction and purification using the Qiagen
AllPrep DNA/RNA FFPE kit. 85ng of input RNA was used to prepare sequencing libraries
using the Illumina TruSeq RNA Exome kit. Sequencing of the RNA Exome libraries was per-
formed on the Illumina HiSeq 4000 instrument at 2 x 75 read paired end configuration. Tran-
scripts were quantified using salmon-v.0.11.2 [9]. A matrix of gene expression values for all
patients analyzed in this study along with matched quantitative IHC are provided as a S1 Table.
Computational analysis of infiltrating cells and comparison of techniques
RNA-Seq-based cell type deconvolution was performed using xCELL (5) and CIBERSORT (6),
with TPM gene expression levels as input. xCELL was used to perform cell type enrichment
analysis from gene expression data for 64 immune and stroma cell types, whereas CIBERSORT
provides absolute and relative abundance of different immune cell types depending on the
specified gene set. In the present analysis, the LM22 signature provided by CIBERSORT was
applied. We also applied EPIC (10) and MCPcounter (11) to estimate the abundance of
immune cell population. EPIC estimates the proportions of Immune and Cancer cells by using
RNA-Seq-based gene expression reference profiles from immune cells and other nonmalig-
nant cell types found in tumors. MCPcounter quantifies abundance of tissue-infiltrating eight
immune and two stromal cell populations based on transcriptome profile.
Initial clustering of patients based on infiltrating cell types was performed using ClusterVis
[10]. Principal components are calculated as described in (6) using ClusterVis (7). Missing
data is assigned using Singular Value Decomposition with imputation iteratively until esti-
mates of missing values converge. Statistical significance of the resulting hierarchical clusters
were assessed using the sigclust2 R package [11]. Correlation between infiltrating cell types cal-
culated using RNA-Seq versus quantitative IHC was performed by generating a composite of
T cell and macrophage cell types determined by RNA-Seq for direct comparison to IHC popu-
lations (Table 2). Correlations between xCELL immune cell type enrichment and quantitative
IHC, as well as between CIBERSORT cell type abundances and quantitative IHC, were deter-
mined by Spearman Rank correlation.
Identification of genes associated with high and low T cell infiltration
Patients were categorized into high and low infiltration of CD3+ and CD8+ T cells according
to quantitative IHC and sub-categorized into those with high infiltration of both populations
PLOS ONE RNASeq analysis of T cell infiltration in pancreatic cancer
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(CD3HICD8HI) versus low infiltration of both populations (CD3LOCD8LO). Using RNA-Seq
data from these patients, gene expression analyses were performed using a univariate two-sam-
ple T-test with a stringent false-positive threshold to identify genes significantly differentially
expressed (p<0.001) in our patients [12, 13]. These genes were mapped to known pathways
using the Reactome Functional Interaction network tool [14]. These genes were tested on the
TCGA Pancreatic Adenocarcinoma PanCancer Atlas [15] as a validation cohort using cBio-
portal [16, 17] where mRNA expression z-scores are compared to the expression distribution
of each gene in tumors that are diploid for this gene. To be classified as enriched for the gene
score the sample must have at least one gene that is 2 log fold overexpressed. Survival and
expression data exported to Graphpad Prism for survival comparison using log-rank tests.
Pre-calculated xCELL analysis of patients in the TCGA database were obtained from http://
xcell.ucsf.edu.
Statistical methods
Survival data were analyzed using Prism (Version 8.4.2, GraphPad Software, La Jolla, CA).
Overall survival of groups was compared using a log rank test for differences in Kaplan-Meier
survival curves. All cutoffs for high/low infiltration by RNA analysis use median values. Gene
expression analyses were performed using a univariate two-sample T-test with a stringent
false-positive threshold to identify genes significantly differentially expressed (p<0.001) [12,
13]. Correlations between immune cell type enrichment and quantitative IHC were deter-
mined by Spearman Rank correlation. To assess the statistical significance of correlation
between RNA-Seq-based cell type deconvolution and CD3, CD8 or CD68 immune cell types
determined by quantitative IHC, the composition of underlying cell types specified in Table 2
were randomly permuted. The number of cells that constitute a cell type were kept the same
between the true set and permuted set. Owing to the number of cell types estimated by xCELL
(64 different cell type populations) and CIBERSORT (22 different cell type populations), we
conducted 100 and 20 different random assignments of cell types, respectively, attributed to
the CD3, CD8 and CD68 IHC populations in Table 2. For each permutation, Spearman rank
correlation was computed between the random cell type assignments and quantitative IHC,
allowing for a level of statistical significance to be estimated for the true set with respect to all
permuted sets, thereby indicating whether the RNA-Seq-based cell type deconvolution meth-
ods are statistically significantly correlated with quantitative IHC. Additional correlations
between multiple variables were analyzed using Prism (Version 8.4.2) to calculate a Pearson
correlation coefficient. Statistical significance of hierarchical clusters were assessed using the
Table 2. Assembly of composite RNASeq-calculated populations to match cell types detected by IHC.
IHC populations CD3 CD8 CD68









CD4+ T-cells CD4+ Tcm Macrophages M1
CD4+ Tem CD8+ naive T-cells Macrophages M2
CD8+ T-cells CD8+ Tcm
CD8+ Tem Tregs
Th1 cells Th2 cells
Tgd cells NKT
https://doi.org/10.1371/journal.pone.0238380.t002
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sigclust2 R package [11]. Differential gene expression analysis between CD3 Hi CD8 HI vs
CD3 Lo CD8 Lo RNA-Seq samples were carried out using DESeq2 [18]. We identified differ-
entially expressed genes, ranked them based on fold-change and p-value. This gene signature
was further used for gene set enrichment.
Results
We previously demonstrated that increased CD3+ T cell infiltrates in surgically resected pan-
creatic adenocarcinoma correlate with improved outcomes using a Cox proportional hazards
model, and remained prognostic by multivariable analysis [1]. By contrast, CD8+ T cell infil-
trates and CD68+ macrophage infiltrates did not correlate with outcome [1]. However, using
categorical variables of high or low CD3+, CD8+ and CD68+ cell numbers in tumors, we were
able to identify cutoffs that demonstrated that patients with high CD3+ T cells or high CD8+ T
cells exhibited improved survival, but again CD68+ macrophages did not correlate with sur-
vival (Fig 1a). To evaluate the complexity of the infiltrate in patient tumors, we performed
hierarchical cluster analysis. Initially, we used our broader dataset that included pancreatic
ductal adenocarcinoma (PDA) with and without neoadjuvant treatment, as well as benign
pancreatic masses, pre-malignant disease, neuroendocrine tumors, as well as a small number
of duodenal adenocarcinoma and gallbladder adenocarcinoma. Principal component analysis
was not able to distinguish these pathologies based on CD3+, CD8+ and CD68+ cell infiltrate
(Fig 1bi), and while cluster analysis tended to group benign and premalignant disease in poorly
infiltrated groups, there was not a clear classifier to distinguish PDA from other related pathol-
ogies (Fig 1bii). Prior studies have demonstrated that patients with the highest macrophage
proportions and lowest CD8+ T cell proportions exhibit worse outcome than those with lowest
macrophage proportions and highest T cell proportions [19]. We calculated the correlation
between CD3+, CD8+ and CD68+ cell infiltrate in patients with all pathologies and those with
PDA and found good correlation between CD3+ and CD8+ infiltrates, and poor, but not nega-
tive, correlation with T cells and CD68+ cell infiltrate (Fig 1c). To determine whether the
degree of CD68+ cell infiltrate impacted outcome for patients with high or low T cell infiltrates,
we tested the effect of CD68+ cell infiltrate with each T cell cutoff. For patients with PDA we
did not find an effect of macrophage infiltration on the survival benefit of CD3+ T cells (Fig
1di and 1dii) or CD8+ T cells (Fig 1diii and 1div). These data demonstrate that quantitative
immunohistology was able to identify good and poor outcome groups based on CD3+ and
CD8+ T cell infiltrate, but analyzing the degree of CD68+ macrophage infiltrate alone or in
combination with T cell infiltrates did not help refine outcome groups.
There are significant limitations in the use of CD68 as a sole marker of macrophages in
tumors [20], particularly in view of the diverging phenotypes macrophages can generate.
There is not a well-defined set of markers that is unique to distinct macrophage polarization
states that do not overlap with other cell types. Recently, a number of algorithms have been
developed that can analyze gene expression data to estimate the prevalence of the broad range
of cell types in a mixed tissue sample [5, 6, 21]. To evaluate whether gene expression analysis
could refine our understanding of the immune environment of pancreatic cancer we tested
two different approaches, CIBERSORT [6] and xCELL [5]. CIBERSORT has been most widely
applied, and provides an assessment of 22 of the most common immune cell types and some
information on the differentiation of CD4+ T cells and macrophages [6]. We performed
RNA-Seq on a subset of our PDA patients with quantitative IHC, and performed CIBERSORT
analysis of immune infiltration using the RNA-Seq data. We used a correlation analysis to
determine whether some cell types were co-regulated in the tumor, but there was little evi-
dence of correlation between the infiltration of different immune cell types in the tumor
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Fig 1. Analysis of patients by quantitative immunohistology. a) Quantitative analysis of infiltrating i) CD3+; ii) CD8+; and iii) CD68+
cells/mm2 tumor were used to set cutoff values of high/low infiltrates with significant impact on overall survival of patients with PDA.
Cutoffs used were approximately CD3 – 75th percentile; CD8 –median; CD68 –no significant cutoff found, 75th percentile shown. b)
Infiltrating CD8+, CD3+, and CD68+ cells across a range of pathologies was used to evaluate principal component analysis and clustering.
i) Unit variance scaling is applied to rows; SVD with imputation is used to calculate principal components. X and Y axis show principal
component 1 and principal component 2 that explain 56.7% and 30.5% of the total variance, respectively. Prediction ellipses are such that
with probability 0.95, a new observation from the same group will fall inside the ellipse. N = 123 data points. ii) Clustering of patients
according to infiltrates. Imputation is used for missing value estimation. Both rows and columns are clustered using Manhattan distance
and complete linkage. 3 rows, 123 columns. c) Pearson correlation coefficients for CD8, CD3 and CD68 infiltrating cells in i) all
PLOS ONE RNASeq analysis of T cell infiltration in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0238380 August 31, 2020 7 / 19
(S1 Fig). We performed cluster analysis on patients based on their immune infiltrates calcu-
lated by CIBERSORT (Fig 2ai), which appeared to identify a diffuse cluster of patients with
higher numbers of CD8 T cells and dendritic cells, but there was no strong statistical associa-
tion between these cell types and this analysis was not able to identify patient groupings with
significant differences in overall survival (not shown). To directly compare these CIBERSORT
calculated infiltrating cell types to the quantified immunohistology from the same samples, we
made three combined groups (Table 2): 1. CD3+ equivalent based on cell types that express
CD3 (Treg+CD4 populations+CD8+gd T cells); CD8+ equivalent (CD8); and CD68+ macro-
phage equivalent (MO+M1+M2). We then evaluated the correlation between infiltration
determined by CIBERSORT analysis of RNA-Seq versus quantified immunohistology. Both
CD3+ and CD8+ T cells showed a weakly positive correlation between the IHC and CIBER-
SORT assessments, but CD68 did not correlate well between histology and CIBERSORT (Fig
2b). Spearman’s rho computed between IHC and CIBERSORT relative cell type abundance
were 0.355, 0.308, 0.144 for CD3, CD8 and CD68 respectively. Notably, we see a number of
patients with no detectable infiltrating T cells or macrophages by CIBERSORT, who did have
detectable cells by histology. Since CIBERSORT is dependent on key RNA transcripts being
present amongst the RNA sequenced, we believe that at low cell infiltration this approach can
struggle to identify the RNA signature of rare infiltrating cells. To determine whether CIBER-
SORT infiltration of these key cell types predicted outcome, we similarly stratified patients
into high or low infiltration groups. We found that patients with high combined CD3+ equiva-
lent scores exhibited improved overall survival (p<0.05), but the CD8 and macrophage scores
were not able to discriminate patients with significantly different overall survival (Fig 2c).
These suggest that while CIBERSORT analysis can provide additional information on the
diversity of immune cells in tumors, it does not improve our ability to predict outcome over
quantitative histology. Since there is a general agreement between the assessment of total CD3
infiltrate by histology and CIBERSORT and each are associated with improved outcome in
patients, aggregating CIBERSORT T cell infiltration could be further tested as a prognostic fac-
tor in pancreatic cancer patients.
As an alternative approach xCELL can identify 64 different cell populations and composite
infiltration scores from RNA-Seq data [5]. We performed xCELL analysis of immune infiltra-
tion in pancreatic cancer and generated a correlation matrix to examine associations between
different cell types. Clear patterns emerged, with some tight clusters based around epithelial
cells or Th2 cells, and more broad groupings of co-regulated cells including Th1 cells, DC, M1
macrophages and CD8 T cells (S2 Fig). To determine whether these co-resident cells identified
unique patient populations, we clustered patients based on their immune infiltrate, identifying
patients with higher levels of CD8 T cells, DC, and M1 macrophages (Cluster A), and those
with higher levels of fibroblasts and endothelial cells to form a distinct cluster (Cluster B) (Fig
3a). Comparing the overall survival of patients in each cluster demonstrated there were no sig-
nificant differences between groups (Fig 3b). In view of the high correlation between specific
cell types resulting in apparent clusters, we investigated whether this was due to closely related
cells having overlapping genes that are included in the underlying gene signature. Using the
gene signatures that determine cell types in xCELL, we computed the percent match between
genes across all cell types (S3 Fig). These data demonstrated that most cells were defined using
a unique gene set. We did identify overlapping gene usage between related cell types such as
pathologies; ii) PDA. d) Overall survival of PDA patients with i) high or ii) low CD3+ infiltrates, and iii) high or iv) low CD8+ infiltrates
subdivided according to high or low CD68 infiltrates as determined in a). Number of patients on each arm of survival curves are shown
in grey.
https://doi.org/10.1371/journal.pone.0238380.g001
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Fig 2. Evaluation of CIBERSORT analysis of immune infiltration. a) Clustering of immune populations inferred using CIBERSORT
analysis of RNASeq of PDA patients. Rows are centered; unit variance scaling is applied to rows. Both rows and columns are clustered
using correlation distance and average linkage. 22 rows, 39 columns. b) The immune infiltrate score of all i) CD3+, ii) CD8+, and iii)
CD68+ equivalent cell populations (Table 2) determined by CIBERSORT compared to quantitative IHC from the same patient. Each
symbol represents one patient. c) Overall survival of patients with high versus low infiltrates of i) CD3+, ii) CD8+, and iii) CD68+
equivalent cell populations (Table 2) determined by median CIBERSORT infiltration. NS = not significant.
https://doi.org/10.1371/journal.pone.0238380.g002
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Fig 3. Evaluation of xCELL analysis of immune infiltration. a) i) Clustering of immune populations inferred using
xCELL analysis of RNASeq of PDA patients. Rows are centered; unit variance scaling is applied to rows. Both rows and
columns are clustered using correlation distance and average linkage. 60 rows, 39 columns. ii) overall survival of
patients in clusters A, B, C, and D. b) The immune infiltrate score of all i) CD3+, ii) CD8+, and iii) CD68+ equivalent
cell populations (Table 2) determined by xCELL compared to quantitative IHC from the same patient. Each symbol
represents one patient. c) Overall survival of patients with high versus low infiltrates of i) CD3+, ii) CD8+, and iii)
CD68+ equivalent cell populations (Table 2) determined by median xCELL infiltration. NS = not significant. d) Overall
survival of patients with high versus low i) immunescore, ii) stromascore, and iii) environment score using median
values as cutoffs.
https://doi.org/10.1371/journal.pone.0238380.g003
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DC subtypes or T cell subtypes; however, there were no significant gene overlaps between DC
and T cells, for example, that would explain their correlation. These suggest that the positive
correlation between the number of T cells and DCs in patient tumors is likely a result of the
presence of both cell types in the analyzed sample. To compare these calculated infiltrating cell
types to quantified immunohistology, we again made three combined groups: 1. CD3 equiva-
lent (Treg + all CD4 populations + all CD8 populations +gd T cells); CD8 equivalent (all CD8
populations); and CD68 macrophage equivalent (MO + M1 + M2) (Table 2). We evaluated the
correlation between cell infiltration assayed by xCELL analysis of RNA-Seq versus quantified
immunohistology. Each population showed a positive correlation between the two approaches;
however, many of the samples were calculated to have no CD8 T cells by xCELL, even in
patients with relatively abundant CD8 T cells as determined by immunohistology (Fig 3b). As
with CIBERSORT analysis, despite the positive correlation, the R2 value was not strong for
each cell type. Spearman’s rho computed between IHC and xCELL were 0.354, 0.307 and 0.144
for CD3, CD8 and CD68 respectively. We also evaluated whether infiltration of these cell types
impacted outcome, and we could not detect a cutoff that impacted overall survival (Fig 3c).
xCELL analysis does calculate three additional fields that integrate many of the infiltrating
cell features to generate an “immunescore”, a “microenvironment score” and a “stromascore”.
Such combined fields may have an advantage over individual cell types, particularly where the
cells are of low abundance. Broadly, the immunescore was correlated with T cell infiltration,
while the stromascore was correlated with fibroblast and endothelial cell infiltration (S3 Fig).
Patients with a high immunescore exhibited improved overall survival, but the stromascore
and the microenvironment score were not able to distinguish patient groups with improved
outcome. These data suggest that xCELL can provide a more complex understanding of the
immune cell diversity in tumors; however, there remain significant issues identifying the small
numbers of T cells infiltrating pancreatic adenocarcinoma. There may be a benefit in integrat-
ing multiple immune cell types through features such as the immunescore to identify tumor
environments indicative of improved outcome.
There are increasing numbers of methods to analyze cell infiltrates from RNA data. We
compared the additional methods EPIC [22] and MCPcounter [23] with the same dataset. The
MCPcounter assessment of T cell infiltration correlated well with the IHC CD3 infiltrate, but
all other analyses had poor correlation to IHC data (S4 Fig). To understand whether there was
agreement amongst the various RNA-based approaches, we analyzed the correlation between
the various infiltrating T cell populations assessed by CIBERSORT, xCELL, MCPcounter, and
EPIC. The correlation between the different approaches using the same RNA dataset was mod-
erate, but the closest correlations were found among CD4 T cell populations and relatively
poor correlations between CD8 T cell populations (S4 Fig). These data suggest that there are
significant differences between the RNA-based approaches and each has difficulty consistently
identifying CD8 T cell infiltrates in T cell poor tumors like pancreatic cancer.
To determine whether there is an alternative RNA signature of high T cell infiltration that
can be used in pancreatic tumors to infer T cell infiltration and assess outcome using RNA-Seq
samples, we identified genes that were enriched in tumors with both high CD3 and high CD8
infiltration or both low CD3 and low CD8 infiltration by quantitative IHC. Class comparison
of gene expression identified a subset of genes that were statistically associated with highly T
cell infiltrated tumors (Table 3, Fig 4a). As would be predicted, these included genes encoding
for CD3 as well as genes involved in T cell signaling such as FYN and LAT. Interestingly, the
gene set includes the immunotherapy target CTLA4 [24], as well as SLAMF6, which is a
marker of progenitor exhausted T cells [25]. To determine whether increased expression of
these genes were useful predictors of outcome in pancreatic cancer patients, we examined
expression of these genes in pancreatic adenocarcinoma patients in the TCGA database [15],
PLOS ONE RNASeq analysis of T cell infiltration in pancreatic cancer
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Fig 4. Class comparison of TPM counts on patients with high T cell infiltrate and validation on TCGA cohort. a) Class
comparison of TPM counts was performed on patients with high CD3+ and high CD8+ infiltrates, as compared to patients with
low CD3+ and low CD8+ infiltrates using the cutoffs applied in Fig 1. Graph shows the clustering of 38 significant genes
(p<0.001). Genes enriched in poorly infiltrated tumors are highlighted in bold. b) The genes enriched in highly infiltrated
tumors were tested using the TCGA PanCan Pancreatic Adenocarcinoma cohort to identify patients with enriched RNA
expression of these genes. Graphs show i) overall survival and ii) disease-free survival for patients in each group. The number of
patients in each group is shown. c) Correlation matrix of the expression of the genes listed in a), and xCELL calculated cell
infiltration for the TCGA PanCan Pancreatic Adenocarcinoma cohort. Rows are centered; no scaling is applied to rows. Both
rows and columns are clustered using Manhattan distance and average linkage. 102 rows, 102 columns. Genes are highlighted
in Blue where positively correlated and Red when negatively correlated. Cell types are highlighted in Green.
https://doi.org/10.1371/journal.pone.0238380.g004
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and their effect on patient outcome. Initial analysis indicated that patients with increased
expression of the genes positively associated with T cell infiltration in our cohort had signifi-
cantly increased overall survival and disease-free survival. However, following curation of the
TCGA dataset according to Peran et al. [26] to remove mischaracterized tumors from the
cohort, overall survival was no longer significantly different, but disease-free survival was sig-
nificantly improved (Fig 4b). These data suggest that the geneset was identifying patients with
neuroendocrine tumors and the improved prognosis of these patients was influencing the
overall survival results in the uncurated dataset. To understand whether the geneset was associ-
ated with increased T cell infiltration, we obtained pre-calculated xCELL analysis of infiltrating
cells in these pancreatic cancer TCGA specimens (https://xcell.ucsf.edu), and examined the
correlation of each cell type with the expression of genes in our panel. To find potential pat-
terns of biological significance, we correlated the expression of the gene set with the infiltration
of immune cells across the TCGA cohort and performed clustering to gather co-regulated
genes and cells together. We discovered that as with our cohort, there was a strong correlation
between infiltrating T cells and dendritic cells in pancreatic tumors, and these correlated
closely with the expression of genes in our panel (Fig 4c). Macrophage and endothelial cell
infiltration did not correlate well with any of the genes in our panel, and smooth muscle cells,
keratinocytes, and epithelial cell infiltration correlated best with some of the genes that were
negatively associated with T cell infiltration, such as NEBL and HSP90AB1. These data indicate
that the gene signature associated with high T cell infiltration in our pancreatic cancer cohort
can similarly identify high T cell infiltration in other pancreatic cancer cohorts represented in
the TCGA database. Further studies are needed to understand whether these genes have func-
tional roles and are potential therapeutic targets.
Discussion
Despite the poor overall prognosis of pancreatic cancer, patients with high numbers of infil-
trating T cells as determined by quantitative immunohistology have improved outcome. To
understand the complexity of the tumor immune environment, we performed RNA-Seq and
evaluated gene expression-based analyses of tumor-infiltrating cells. We found that there were
limitations in current gene expression analyses of infiltrating immune cells, particularly where
overall infiltration was low. Both CIBERSORT and xCELL showed poor concordance with
IHC, and individual immune cell types identified by gene expression analysis had limited
prognostic value. This could be somewhat overcome by aggregating molecularly-identified
immune populations, for example into total T cell infiltrates, which showed some correlation
to quantitative immunohistology and could be predictive of outcome. To determine if we
could identify alternative molecular signatures of highly infiltrated tumors, we performed class
comparison of gene expression and identified a transcriptional pattern in pancreatic adenocar-
cinoma that had predictive value for disease-free survival in the TCGA cohort.
Immunohistology with validated antibodies is the gold standard for quantitative assessment
of infiltrating immune cells in cancer [27]. However, the diversity of cell types and limited
number of cell-type specific markers makes it difficult to accurately assess many infiltrating
cell types using histology. Flow cytometry is more able to address this diversity, using a series
of gates to distinguish cell subtypes expressing multiple overlapping markers; however, this
cannot be performed with archived tissues. The recent improvement in image analysis and
technological improvements in multiplex staining has permitted much more complex assess-
ment of tumors using immunohistology [28]. This is critical since many of our single markers
have limitations. For example, our study used CD68 as a well-validated marker for tumor asso-
ciated macrophages. However, there are significant limitations in the use of CD68 as a sole
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marker of macrophages in tumors [20], particularly in view of the diverging phenotypes mac-
rophages can generate. In particular, while there may be a spectrum of macrophage pheno-
types [29], the polarized M1 (classical) versus M2 (alternative) macrophage phenotype has
proven useful in discriminating macrophages that support versus suppress adaptive immunity
to tumors [30–33]. Therefore, the presence of macrophages does not necessarily indicate that
they generate immune suppression in the tumor.
The recent development of algorithms that can analyze gene expression data to estimate
the prevalence of the broad range of cell types in a mixed tissue samples, combined with the
increasing affordability of comprehensive genomic profiling of patient tumors, has opened
new avenues of research [21]. While gene expression data can provide a great deal of informa-
tion from small quantities of tissue, there are potential issues in estimating immune cell num-
bers in pancreatic tumors, since the abundance of some of these populations can be very low
even when they have prognostic significance. For example, xCELL gene signatures were identi-
fied using purified populations and validated on peripheral blood samples [5], which have a
very different immune cell abundance when compared to tumors. CIBERSORT was shown to
have superior performance to other approaches available at the time to assess immune infil-
trating cells from genomic data [6]; however, performance was limited when the target
immune populations represented fewer than 1% of the spiked mixture. Each approach pro-
vides valuable information on immune infiltration and may be sufficient to assess the environ-
ment of more abundantly infiltrated tumors. However, there are limitations based on the
number of RNA reads provided by each infiltrating cell in a bulk population. Immunohistol-
ogy has its own limitations, particularly those relating to epitope preservation through tissue
processing, and the difficulties in standardizing staining over time and between institutions. In
this study we set quantitative immunohistology as the gold standard for comparison; however,
standard sampling issues such as selection of an appropriate archived tissue block and the rele-
vance of a single 5μM section to the tissue as a whole can lead to inaccuracies that apply to
each approach. Novel technologies are emerging that incorporate the geographic information
of histology with comprehensive gene profiling, and have the potential to change how we
assess the immune complexity of tumors [34]. Further analysis of patients giving discordant
RNA and IHC data would be valuable to understand the impact of sampling versus other com-
plicating factors that could explain the variations.
The strength of genomic and other omic profiling is the wealth of data that can be extracted
simultaneously. Along with infiltrating cells, omic analyses can inform as to the mutational sta-
tus of the tumor [8] to identify immunotherapeutic targets [35], and identify expression of
inflammatory and chemokine markers that may dictate immune cell recruitment [36, 37].
Such analyses would be best combined with genomic analysis approaches that subdivide
patients according to novel molecular subtypes, some of which include tumor subtypes associ-
ated with higher immune infiltrates [38, 39]. However, further subdivision of patients will
require much larger cohorts to generate meaningful results. All of this can be performed on
very small quantities of patient material, at decreasing cost and with increasing speed. While
IHC-based multiplexing continues to increase the number of analytes that can be assessed on a
single tissue sample, this approach depends on the availability of high-quality validated anti-
bodies for each target. Unbiased sequencing-based approaches are to some degree future-
proofed against genes that may be of interest yet do not currently have reagents for IHC or
other analyses.
Further refinement of gene expression profiling for pancreatic adenocarcinoma and similar
poorly infiltrated tumors could have significant benefits in personalizing immunotherapy for
these recalcitrant tumors. For example, we show that CTLA4 is enriched in patients with high
PLOS ONE RNASeq analysis of T cell infiltration in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0238380 August 31, 2020 15 / 19
T cell infiltration and is part of the gene set that is associated with improved disease free sur-
vival. Antibodies targeting CTLA4 are an effective immunotherapy in some tumors [40], but
single agent anti-CTLA4 is not effective in patients with locally advanced and metastatic pan-
creatic adenocarcinoma [41]. In preclinical models of pancreatic adenocarcinoma, we simi-
larly found that anti-CTLA4 is ineffective as a single agent [42]. The combination of anti-
CTLA4 and radiation therapy is curative, but only where the host has good pre-existing immu-
nity to the tumor. Thus, gene expression profiling may help identify patient subsets with ade-
quate T cell infiltration that may benefit from immunotherapy combinations, and direct other
patients to novel interventions to improve their tumor immune environment prior to further
treatment.
Conclusions
While immunotherapy options are currently limited for patients with pancreatic adenocarci-
noma, these and other data showing an impact of immune infiltrates on patient outcomes sug-
gests we should continue to refine our understanding of the immune environment and pursue
immune therapies that are appropriate to the particular tumor environments of pancreatic
cancer. At present RNASeq-based analyses must take into account the poor overall infiltrate in
some tumor types to provide accurate assessments of the tumor environment.
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